ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (audio)

Info
Chat en Directo Comentarios

Medicina, #asco, #cancer, #cancergrace, #david, #dr, #edward, #geffen, #grace, #gracecast, #heat, #highlights, #hsp90, #inhibitor, #lung, #medicine, #of, #protein, #school, #shock, #ucla

Featured This Week
Spreaker's Prime Shows
Staff Picks
Crime
This NFL life 🏈
Descubrir más

Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.

Autor

cancerGRACE Meetings 2 followers Follow